Skip to main content
Top
Published in: Cancer Cell International 1/2013

Open Access 01-12-2013 | Primary research

Functional features of cancer stem cells in melanoma cell lines

Authors: Rüdiger M Zimmerer, Philippe Korn, Philippe Demougin, Andreas Kampmann, Horst Kokemüller, André M Eckardt, Nils-Claudius Gellrich, Frank Tavassol

Published in: Cancer Cell International | Issue 1/2013

Login to get access

Abstract

Background

Recent evidence suggests a subset of cells within a tumor with "stem-like" characteristics. These cells are able to transplant tumors in immunodeficient hosts. Distinct from non-malignant stem cells, cancer stem cells (CSC) show low proliferative rates, high self-renewing capacity, propensity to differentiate into actively proliferating tumor cells, and resistance to chemotherapy or radiation. They are often characterized by elevated expression of stem cell surface markers, in particular CD133, and sets of differentially expressed stem cell-associated genes. CSC are usually rare in clinical specimens and hardly amenable to functional studies and gene expression profiling. In this study, a panel of heterogenous melanoma cell lines was screened for typical CSC features.

Methods

Nine heterogeneous metastatic melanoma cell lines including D10 and WM115 were studied. Cell lines were phenotyped using flow cytometry and clonogenic assays were performed by limiting dilution analysis on magnetically sorted cells. Spheroidal growth was investigated in pretreated flasks. Gene expression profiles were assessed by using real-time rt-PCR and DNA microarrays. Magnetically sorted tumor cells were subcutaneously injected into the flanks of immunodeficient mice. Comparative immunohistochemistry was performed on xenografts and primary human melanoma sections.

Results

D10 cells expressed CD133 with a significantly higher clonogenic capacity as compared to CD133- cells. Na8, D10, and HBL cells formed spheroids on poly-HEMA-coated flasks. D10, Me39, RE, and WM115 cells expressed at least 2 of the 3 regulatory core transcription factors SOX2, NANOG, and OCT4 involved in the maintenance of stemness in mesenchymal stem cells. Gene expression profiling on CD133+ and CD133- D10 cells revealed 68 up- and 47 downregulated genes (+/-1.3 fold). Two genes, MGP and PROM1 (CD133), were outstandingly upregulated. CD133+ D10 cells formed tumors in NSG mice contrary to CD133- cells and CD133 expression was detected in xenografts and primary human melanoma sections using immunohistochemistry.

Conclusions

Established melanoma cell lines exhibit, to variable extents, the typical features of CSCs. The tumorigenic cell line D10, expressing CD133 and growing in spheroids and might qualify as a potential model of melanoma CSCs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chen AY, Desantis C, Jemal A: US mortality rates for oral cavity and pharyngeal cancer by educational attainment. Arch Otolaryngol Head Neck Surg. 2011, 11: 1094-1099.CrossRef Chen AY, Desantis C, Jemal A: US mortality rates for oral cavity and pharyngeal cancer by educational attainment. Arch Otolaryngol Head Neck Surg. 2011, 11: 1094-1099.CrossRef
2.
go back to reference Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth A, Busam K: Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol. 2008, 14: 2299-2304.CrossRef Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth A, Busam K: Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol. 2008, 14: 2299-2304.CrossRef
3.
go back to reference Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U: Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Res. 2008, 1: 61-67.CrossRef Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U: Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Res. 2008, 1: 61-67.CrossRef
4.
go back to reference Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U: Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res. 2008, 2: 152-160.CrossRef Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U: Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res. 2008, 2: 152-160.CrossRef
5.
go back to reference Garbe C, Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U: Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges = Journal of the German Society of, Dermatology. 2008, 6: S9-S14. Garbe C, Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U: Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges = Journal of the German Society of, Dermatology. 2008, 6: S9-S14.
7.
go back to reference Chapman PB: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011, 26: 2507-2516.CrossRef Chapman PB: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011, 26: 2507-2516.CrossRef
8.
go back to reference Hamburger A, Salmon SE: Primary bioassay of human myeloma stem cells. J Clin Invest. 1977, 4: 846-854.CrossRef Hamburger A, Salmon SE: Primary bioassay of human myeloma stem cells. J Clin Invest. 1977, 4: 846-854.CrossRef
9.
go back to reference Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997, 7: 30-737. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997, 7: 30-737.
10.
go back to reference Mizrak D, Brittan M, Alison MR: CD133: molecule of the moment. J Path. 2008, 214: 3-9. 10.1002/path.2283.CrossRefPubMed Mizrak D, Brittan M, Alison MR: CD133: molecule of the moment. J Path. 2008, 214: 3-9. 10.1002/path.2283.CrossRefPubMed
11.
go back to reference Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003, 7: 3983-3988.CrossRef Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003, 7: 3983-3988.CrossRef
12.
go back to reference Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature. 2000, 6801: 249-257.CrossRef Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature. 2000, 6801: 249-257.CrossRef
13.
go back to reference Pouysségur J, Dayan F, Mazure NM: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006, 7092: 437-443.CrossRef Pouysségur J, Dayan F, Mazure NM: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006, 7092: 437-443.CrossRef
14.
go back to reference Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005, 20: 9328-9337.CrossRef Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005, 20: 9328-9337.CrossRef
15.
go back to reference Tavaluc RT, Hart LS, Dicker DT, El-Deiry WS: Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. Cell Cycle. 2007, 20: 2554-2562.CrossRef Tavaluc RT, Hart LS, Dicker DT, El-Deiry WS: Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. Cell Cycle. 2007, 20: 2554-2562.CrossRef
16.
go back to reference Zhou J, Zhang Y: Cancer stem cells: Models, mechanisms and implications for improved treatment. Cell Cycle. 2008, 10: 1360-1370.CrossRef Zhou J, Zhang Y: Cancer stem cells: Models, mechanisms and implications for improved treatment. Cell Cycle. 2008, 10: 1360-1370.CrossRef
17.
go back to reference Schmidt P, Abken H: The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth. Oncotarget. 2011, 4: 313-320.CrossRef Schmidt P, Abken H: The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth. Oncotarget. 2011, 4: 313-320.CrossRef
18.
go back to reference Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M: Identification of cells initiating human melanomas. Nature. 2008, 7176: 345-349.CrossRef Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M: Identification of cells initiating human melanomas. Nature. 2008, 7176: 345-349.CrossRef
19.
go back to reference Clevers H: The cancer stem cell: premises, promises and challenges. Nat Med. 2011, 3: 313-319.CrossRef Clevers H: The cancer stem cell: premises, promises and challenges. Nat Med. 2011, 3: 313-319.CrossRef
20.
go back to reference Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C: Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 2007, 5: 935-946.CrossRef Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C: Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 2007, 5: 935-946.CrossRef
21.
go back to reference La Porta CAM, Porro D, Comolli R: Higher levels of melanin and inhibition of cdk2 activity in primary human melanoma cells WM115 overexpressing nPKCdelta. Melanoma Res. 2002, 4: 297-307.CrossRef La Porta CAM, Porro D, Comolli R: Higher levels of melanin and inhibition of cdk2 activity in primary human melanoma cells WM115 overexpressing nPKCdelta. Melanoma Res. 2002, 4: 297-307.CrossRef
22.
go back to reference Hyslop L, Stojkovic M, Armstrong L, Walter T, Stojkovic P, Przyborski S: Downregulation of NANOG induces differentiation of human embryonic stem cells to extraembryonic lineages. Stem Cells. 2005, 8: 1035-1043.CrossRef Hyslop L, Stojkovic M, Armstrong L, Walter T, Stojkovic P, Przyborski S: Downregulation of NANOG induces differentiation of human embryonic stem cells to extraembryonic lineages. Stem Cells. 2005, 8: 1035-1043.CrossRef
23.
go back to reference Clark AT, Rodriguez RT, Bodnar MS, Abeyta MJ, Cedars MI, Turek PJ: Human STELLAR, NANOG, and GDF3 genes are expressed in pluripotent cells and map to chromosome 12p13, a hotspot for teratocarcinoma. Stem Cells. 2004, 2: 169-179.CrossRef Clark AT, Rodriguez RT, Bodnar MS, Abeyta MJ, Cedars MI, Turek PJ: Human STELLAR, NANOG, and GDF3 genes are expressed in pluripotent cells and map to chromosome 12p13, a hotspot for teratocarcinoma. Stem Cells. 2004, 2: 169-179.CrossRef
24.
go back to reference Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E, Xu Y: p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol. 2005, 2: 165-171.CrossRef Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E, Xu Y: p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol. 2005, 2: 165-171.CrossRef
25.
go back to reference Civenni G, Walter A, Kobert N, Mihic-Probst D, Zipser M, Belloni B, Seifert B, Moch H, Dummer R, van den Broek M, Sommer L: Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 2011, 8: 3098-3109.CrossRef Civenni G, Walter A, Kobert N, Mihic-Probst D, Zipser M, Belloni B, Seifert B, Moch H, Dummer R, van den Broek M, Sommer L: Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 2011, 8: 3098-3109.CrossRef
26.
go back to reference Lai CY, Schwartz BE, Hsu MY: CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry. Cancer Res. 2012, 72: 5111-5118. 10.1158/0008-5472.CAN-12-0624.PubMedCentralCrossRefPubMed Lai CY, Schwartz BE, Hsu MY: CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry. Cancer Res. 2012, 72: 5111-5118. 10.1158/0008-5472.CAN-12-0624.PubMedCentralCrossRefPubMed
27.
go back to reference Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Braford PA, Vultur A: A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuos tumor growth. Cell. 2010, 141: 583-594. 10.1016/j.cell.2010.04.020.PubMedCentralCrossRefPubMed Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Braford PA, Vultur A: A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuos tumor growth. Cell. 2010, 141: 583-594. 10.1016/j.cell.2010.04.020.PubMedCentralCrossRefPubMed
28.
go back to reference Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D’Angelica M, Kemeny N, Lyden D, Rafii S: CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008, 118 (6): 2111-2120.PubMedCentralPubMed Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D’Angelica M, Kemeny N, Lyden D, Rafii S: CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008, 118 (6): 2111-2120.PubMedCentralPubMed
29.
go back to reference Hilmi C, Larribere L, Giuliano S, Bille K, Ortonne JP, Ballotti R, Bertolotto C: IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol. 2008, 6: 1499-1505.CrossRef Hilmi C, Larribere L, Giuliano S, Bille K, Ortonne JP, Ballotti R, Bertolotto C: IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol. 2008, 6: 1499-1505.CrossRef
30.
go back to reference Frisan T, Levitsky V, Masucci M: Limiting dilution assay. Methods Mol Biol. 2001, 174: 213-216.PubMed Frisan T, Levitsky V, Masucci M: Limiting dilution assay. Methods Mol Biol. 2001, 174: 213-216.PubMed
31.
go back to reference Spagnoli GC, Schaefer C, Willimann TE, Kocher T, Amoroso A, Juretic A: Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Int J Cancer. 1995, 5: 309-315.CrossRef Spagnoli GC, Schaefer C, Willimann TE, Kocher T, Amoroso A, Juretic A: Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients. Int J Cancer. 1995, 5: 309-315.CrossRef
32.
go back to reference Spagnoli GC, Kloth J, Terracciano L, Trutmann M, Chklovskaia E, Remmel E, Noppen C, Zajac P, Kocher T, Heberer M: FLT3 ligand gene expression and protein production in human colorectal cancer cell lines and clinical tumor specimens. Int J Cancer. 2000, 86: 238-243. 10.1002/(SICI)1097-0215(20000415)86:2<238::AID-IJC13>3.0.CO;2-X.CrossRefPubMed Spagnoli GC, Kloth J, Terracciano L, Trutmann M, Chklovskaia E, Remmel E, Noppen C, Zajac P, Kocher T, Heberer M: FLT3 ligand gene expression and protein production in human colorectal cancer cell lines and clinical tumor specimens. Int J Cancer. 2000, 86: 238-243. 10.1002/(SICI)1097-0215(20000415)86:2<238::AID-IJC13>3.0.CO;2-X.CrossRefPubMed
33.
go back to reference Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 1 (9): 29-45. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 1 (9): 29-45.
34.
go back to reference Thomas PD, Kejariwal A, Campbell MJ, Mi H, Diemer K, Guo N, Ladunga I, Ulitsky-Lazareva B, Muruganujan A, Rabkin S, Vandergriff JA, Doremieux O: PANTHER, a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucl Acids Res. 2003, 31: 334-341. 10.1093/nar/gkg115.PubMedCentralCrossRefPubMed Thomas PD, Kejariwal A, Campbell MJ, Mi H, Diemer K, Guo N, Ladunga I, Ulitsky-Lazareva B, Muruganujan A, Rabkin S, Vandergriff JA, Doremieux O: PANTHER, a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucl Acids Res. 2003, 31: 334-341. 10.1093/nar/gkg115.PubMedCentralCrossRefPubMed
Metadata
Title
Functional features of cancer stem cells in melanoma cell lines
Authors
Rüdiger M Zimmerer
Philippe Korn
Philippe Demougin
Andreas Kampmann
Horst Kokemüller
André M Eckardt
Nils-Claudius Gellrich
Frank Tavassol
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2013
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-13-78

Other articles of this Issue 1/2013

Cancer Cell International 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine